A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Novo Nordisk (Denmark) · University of Minnesota Medical Center · +7 more institutions
Indexed incrossrefpubmed
Abstract
Background
Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity.
Methods
In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to
Citation impact
652
total citations
- FWCI
- 40.46
- Percentile
- 100%
- References
- 34
Citations per year
Authors
9- ASAaron S. KellyCorresponding
Novo Nordisk (Denmark), University of Minnesota Medical Center
- PAPernille Auerbach
Novo Nordisk (Denmark)
- MBMargarita Barrientos‐Pérez
Novo Nordisk (Denmark)
- IGInge Gies
Novo Nordisk (Denmark), Universitair Ziekenhuis Brussel
- PMPaula M. Hale
Novo Nordisk (Denmark), Novo Nordisk (United States)
Topics & keywords
Topics
Keywords
- Liraglutide
- Medicine
- Placebo
- Obesity
- Body mass index
- Confidence interval
- Weight loss
- Randomized controlled trial
No related works found for this paper.